

2015

Adverse events following influenza immunization reported by healthcare personnel using active surveillance based on text messages

L Tracey

A Regan

D Mak

The University of Notre Dame Australia, donna.mak@nd.edu.au

P Effler

Follow this and additional works at: https://researchonline.nd.edu.au/med_article

Part of the [Medicine and Health Sciences Commons](#)

This article was originally published as:

Tracey, L., Regan, A., Mak, D., & Effler, P. (2015). Adverse events following influenza immunization reported by healthcare personnel using active surveillance based on text messages. *Infection Control and Hospital Epidemiology*, 36 (5), 608-610.

Original article available here:

<https://doi.org/10.1017/ice.2015.16>

This article is posted on ResearchOnline@ND at

https://researchonline.nd.edu.au/med_article/817. For more information, please contact researchonline@nd.edu.au.

This is the author's version of an article published in *Infection Control and Hospital Epidemiology*, May 2015, available online at <https://doi.org/10.1017/ice.2015.16>

Tracey, L., Regan, A., Mak, D., and Effler, P. (2015) Adverse events following influenza immunization reported by healthcare personnel using active surveillance based on text messages. *Infection Control and Hospital Epidemiology*, 36(5), 608-610.
doi: [10.1017/ice.2015.16](https://doi.org/10.1017/ice.2015.16)

Infection Control and Hospital Epidemiology

Adverse events following influenza immunisation reported by healthcare personnel using SMS-based active surveillance

--Manuscript Draft--

Manuscript Number:	34951R1
Full Title:	Adverse events following influenza immunisation reported by healthcare personnel using SMS-based active surveillance
Short Title:	Adverse events following immunisation in HCP
Article Type:	Research Brief
Corresponding Author:	Lauren E Tracey, MPH Western Australian Department of Health Shenton Park, WA AUSTRALIA
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	Western Australian Department of Health
Corresponding Author's Secondary Institution:	
First Author:	Lauren E Tracey, MPH
First Author Secondary Information:	
Order of Authors:	Lauren E Tracey, MPH Annette K Regan, MPH Donna B Mak, MPH Paul V Effler, MD
Order of Authors Secondary Information:	
Abstract:	Studies have demonstrated that healthcare personnel (HCP) have concerns about the potential side effects of trivalent inactivate influenza vaccine (IIV3). ¹⁻³ A recent meta-analysis of reasons HCP refuse IIV3 indicates the strongest predictors of vaccine acceptance are belief that the vaccine is safe and belief the vaccine does not cause the disease it is meant to prevent. ¹

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

**Adverse events following influenza immunisation reported by healthcare
personnel using SMS-based active surveillance**

Tracey L, MPH^a Regan AK, MPH^{a,b} Mak, DB, MPH^{a,c}, Effler PV, MD^{a,b}

^a **Communicable Disease Control Directorate, Western Australian Department
of Health, Perth, Western Australia, Australia**

^b **School of Pathology and Laboratory Medicine, University of Western
Australia, Perth, Western Australia, Australia**

^c **School of Medicine, University of Notre Dame, Fremantle, Western Australia,
Australia**

SHORT TITLE: Adverse events following immunisation in HCP

Contact details: Lauren Tracey, Epidemiologist, Communicable Disease Control
Directorate, Western Australian Department of Health; Mailing: 227 Stubbs Terrace,
Shenton Park, Western Australia, 6008, Australia; Phone: +61 89388 4876, Email:
Lauren.Tracey@health.wa.gov.au

Word count: 903

Introduction

1
2 Studies have demonstrated that healthcare personnel (HCP) have concerns about
3
4 the potential side effects of trivalent inactivate influenza vaccine (IIV3).¹⁻³ A recent
5
6 meta-analysis of reasons HCP refuse IIV3 indicates the strongest predictors of
7
8 vaccine acceptance are belief that the vaccine is safe and belief the vaccine does
9
10
11
12 not cause the disease it is meant to prevent.¹
13
14
15
16

17 Timely vaccine safety information for each new seasonal IIV3 vaccine can be used
18
19 to reassure HCP. In addition, the ability to provide real-time safety profiling of new
20
21 vaccines should form part of emergency preparedness planning, for example in the
22
23 case of rapid development and rollout of vaccines in a pandemic.
24
25
26
27
28

29 Despite ready access to vaccines and concerted efforts to promote uptake, influenza
30
31 vaccination coverage among HCP in Australia has historically been low, ranging
32
33 from 18-66%.⁵ In a review of 32 studies from the United States (13), Canada (5),
34
35 Europe (11) and others (3), Hofmann et al. found influenza vaccine coverage of less
36
37 than 50% in HCP in the majority (26/32, 81%) of these studies.⁶
38
39
40
41
42

43 In 2014, the Western Australian Department of Health (“WA Health”) developed the
44
45 Follow-up and Active Surveillance of Trivalent Influenza Vaccine in HCP
46
47 (FASTHealth) program. FASTHealth is an SMS-based, active influenza vaccine
48
49 safety monitoring program intended to be implemented at the start of each season’s
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Methods

1
2 WA Health provides free IIV3 for staff working in government health facilities and
3
4 maintains a centralised record keeping system for recording HCP influenza
5
6 immunisation. In 2014, HCP were asked at the time of vaccination to participate in
7
8 the FASTHealth program to monitor adverse events following immunisation (AEFIs).
9
10 HCP who consented and provided a mobile phone number were sent a text
11
12 message (or 'SMS') seven days after vaccination querying whether they had
13
14 experienced any 'reaction, fever or illness' following vaccination.
15
16
17
18
19
20

21
22 A second SMS was sent 24 hours later to anyone who did not reply to the first
23
24 message. HCP who responded "Yes" to either message were sent a link to a mobile
25
26 phone survey to record the details of their AEFI. Those who opted not to complete
27
28 the smart phone survey and those who did not reply to either SMS were telephoned
29
30 to ascertain specifics of any AEFI via a standardised interview with a research nurse.
31
32 Both surveys were identical in content and asked whether the participant
33
34 experienced fever, headache, fatigue, vomiting, rash, rigors, convulsions or swelling
35
36 or pain at the injection site. Other reported potential side-effects were recorded
37
38
39
40
41 *verbatim/as written.*
42
43
44
45

Results

46
47 Between 19 March and 20 May 2014, 1,624 HCP, including medical, administration
48
49 and support staff, were sent an SMS soliciting whether they experienced an AEFI.
50
51 The majority were female (81%) and between 18-44 years of age (56%); 835 HCP
52
53 received intradermal IIV3 (Intanza®: 51.4%) and 789 received an intramuscular IIV3
54
55 (Vaxigrip®: 48.3%; Fluvax®: 0.3%).
56
57
58
59
60
61
62
63
64
65

1 Of those who were sent an SMS message, 1,432 (88%) replied. A total of 239
2 (17%) of the respondents replied affirmatively that they had experienced one or more
3 reactions to the vaccine. Of those reporting reactions, 184 (77%) provided details
4 regarding the AEFI: 66 via the mobile phone survey and 118 by telephone. The
5 remaining 55 HCP were lost to follow-up.
6
7
8
9
10

11
12
13 Among the 192 HCP who did not reply to the SMS, 65 (34%) were subsequently
14 reached by telephone and 20 (31%) of these reported an event. In aggregate, 1,442
15 HCP provided complete information regarding the occurrence of AEFI, of which 204
16 (14.1% [95% CI 12.2-16.1%]) reported at least one reaction (Figure).
17
18
19
20
21
22
23
24
25

26
27 **Figure. Responses to the FASTHealth program 19 March – 20 May 2014.**
28
29
30

31 No severe adverse events were reported. A total of 137 HCP reported at least one
32 systemic symptom, most commonly fatigue (3.8% [95% CI 2.8-4.8%]), headache
33 (3.7% [95% CI 2.7-4.7%]) or respiratory symptoms (3.7% [95% CI 2.7-4.7%]). 115
34 HCP reported redness, pain or swelling at the injection site (8.0% [95% CI 6.5-
35 1.7%]). These results were in keeping with the documented safety profile of IIV3
36 vaccine.
37
38
39
40
41
42
43
44
45
46
47

48 **Discussion**
49
50

51 Use of SMS technology in the FASTHealth program allowed rapid, active
52 surveillance of the safety of IIV3 offered free to HCP as part of the annual influenza
53 program. Consistent with previous vaccine safety investigations of seasonal IIV3 in
54 HCP, the proportion reporting a potential side-effect was low.^{4,7}
55
56
57
58
59
60
61
62
63
64
65

1 As the antigenic components of the influenza vaccine can change season-to-season
2 and safety profiles from previous seasons' formulations may not be applicable to
3 current vaccines, it is particularly important to monitor the safety of IIV3 each year.
4
5 Our findings demonstrate the feasibility of implementing a timely, resource-
6
7 conserving, vaccine safety monitoring system among HCP each year during
8
9 influenza vaccination season.
10
11
12
13
14
15
16

17 Previous methods to capture AEFI following IIV3 in HCP mainly include self-report
18
19 paper questionnaires, which require significantly more time to capture, record and
20
21 analyse the data.^{4,7,8} Smartphone penetration in Australia was reported at 65% in
22
23 2013, making it a suitable market for the use of such technology.⁸ In the same
24
25 survey, smartphone use is reportedly less common in other countries such as the
26
27 United Kingdom (62%) and the United States (56%), however overall there is
28
29 increasing smartphone penetration globally, and in future the use of this technology
30
31 has applications any time a new vaccine is introduced.⁹
32
33
34
35
36
37
38

39 The information obtained can be used to reassure HCP regarding the reactogenicity
40
41 of the vaccine, and potentially used to improve uptake among HCP. Future studies
42
43 should investigate communication strategies for informing HCP about the safety of
44
45 IIV3. Considering the potential to prevent disease in HCP, their families and their
46
47 patients, opportunities to disseminate safety data to HCP in real time should be
48
49 further explored.
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Acknowledgements

Financial Support:

The FASTHealth program is funded by the Department of Health, Western Australia

Potential Conflicts of Interest:

All Authors report no conflicts of interest relevant to this letter

Thank-yous:

The Authors would like to acknowledge the work of the Research Nurses at the Vaccine Trials Group, Telethon Kids Institute, for their work in telephone follow up of the adverse events, and Sharon Gough for her assistance in data management of the program.

References

1. Vasilevska, M., Ku, J and Fisman, DN, Factors Associated with Healthcare Worker Acceptance of Vaccination: A Systematic Review and Meta-analysis. *Infect Control Hosp Epidemiol*, 2014. 35(6): p. 699-708.
2. Skowronski, DM, Parker, R, and Strang, R, The importance of influenza immunizations for health-care workers. *BCMJ*, 2000. 42(2): p. 91-3.
3. Loulergue, P, et al., Knowledge, attitudes and vaccination coverage of healthcare workers regarding occupational vaccinations. *Vaccine*, 2009. 31(24): p. 4240-3.
4. McEvoy, SP, A retrospective survey of the safety of trivalent influenza vaccine among adults working in healthcare setting in south metropolitan Perth, Western Australia, in 2010. *Vaccine*. 2012. 30(17): p. 2801-4.
5. Seale, H and MacIntyre, CR, Seasonal influenza vaccination in Australia hospital health care workers: a review. *Med J Aust*, 2011. 195(6): p. 336-8.
6. Hofmann F, Ferracin C, Marsh G and Dumas R. Influenza Vaccination of Healthcare Workers: a Literature Review of Attitudes and Beliefs. *Infection*. 2006. 34(3): p.142-7.
7. Ankrah, DNA, et al., Incidence of adverse events among healthcare workers following H1N1 mass immunization in Ghana. *Drug Safety*, 2013. 36(4): p. 259-66.
8. Scheifele, DW, Bjornson, G, and Johnston, J. Evaluation of adverse events after influenza vaccination in hospital personnel. *CMAJ*, 1990.142(2):p.127-30.

9. Think With Google. Our Mobile Planet: Understanding the Mobile Consumer.

Data sets and country reports. 2013. Accessed 01 January 2015. Available from:

<http://think.withgoogle.com/mobileplanet/en/downloads/>.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure

